Sign in
Active, not recruitingNo phase

Effect of Treatment With Butyric Acid in Anorexia Nervosa

Key facts

Who runs it
Azienda Ospedaliero-Universitaria Careggi
Where
Italy1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
50 people, planned
Started
12 Nov 2025
Expected to end
12 Nov 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dietary Supplement: Butyric Acid
Record updated
17 December 2025

Who can take part

Age
18 years to 65 years
Sex
Women only
Healthy volunteers
Cannot take part
Show the full registry criteria (19)Hide the full registry criteria

Who can take part

  • Female sex
  • Age 18-65 years
  • Current diagnosis of Anorexia Nervosa (DSM-5)
  • Able and willing to provide informed consent
  • Ability to comply with study procedures and assessments

Who cannot take part

  • Corticosteroid therapy within the past 6 months
  • Severe psychiatric conditions requiring inpatient hospitalization (e.g., psychosis, severe major depressive episode with suicidal intent)
  • Severe medical conditions requiring inpatient care (cardiovascular, renal, hematopoietic, gastrointestinal, endocrine disorders)
  • Intellectual disability, illiteracy, or conditions impairing consent or questionnaire completion
  • Radiological evidence of toxic megacolon or intestinal perforation
  • Active or past malignancy requiring chemotherapy
  • HIV infection
  • Neutropenia (<0.5 × 10\^9/L)
  • Leukocytosis (>30 × 10\^9/L)
  • Current participation in another experimental protocol
  • Active use of probiotics
  • Fever > 38°C
  • Presence of colostomy
  • Severe comorbidity limiting 30-day survival

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This clinical trial aims to evaluate the therapeutic potential of oral butyric acid supplementation in individuals with anorexia nervosa (AN). T The study will assess whether butyric acid, administered alongside standard multidisciplinary care, improves weight restoration and contributes to overall clinical recovery.

Read full original descriptionShow less

The primary objectives are to determine:

- Whether butyric acid enhances weight restoration during the first 3 months of treatment.

Participants will be randomly assigned to receive either butyric acid or a placebo for 3 months, in addition to treatment-as-usual, which includes nutritional rehabilitation and cognitive-behavioral therapy.

Throughout the study, researchers will monitor:

* Changes in body weight and Body Mass Index (BMI) * General and eating-disorder-related psychopathology * Blood-based biomarkers related to inflammation, metabolism, and neuroendocrine function * Gut microbiota composition and metabolites, including short-chain fatty acids

A total of 50 participants with AN are expected to be enrolled.

The 2 groups in the trial

  • Active Comparator: Butyric AcidExisting treatment, for comparison

    Participants with anorexia nervosa receiving butyric acid supplementation plus Treatment As Usual.

    Treatment: Dietary Supplement: Butyric Acid

  • Placebo Comparator: PlaceboPlacebo, for comparison

    Participants with anorexia nervosa receiving placebo capsules plus Treatment As Usual.

    Treatment: Dietary Supplement: Butyric Acid

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effetto Del Trattamento Con Acido Butirrico Sull'Anoressia Nervosa
Record updated
17 December 2025